Zara Fulton
Scientific Analyst
USA
8+ years of experience
In her role, Zara creates and publishes current, client-focused content including comments, KOL interviews andsurveys, conference reports and webinars.
Prior to joining Pharma Intelligence in 2016, Zara worked as a scientist at The Janssen Pharmaceutical Companies of Johnson & Johnson. While there she worked on a vaccine for Alzheimer's disease. During her time as a Postdoctoral Research Associate at The Scripps Research Institute, she worked on a vaccine for HIV.
With her training as a Structural Biologist, Zara is able to provide insight into the mechanicism of action of drugs in clinical development at the molecular level.
Datamonitor Healthcare
By Zara Fulton 07 Oct 2017
Allergan’s deal with the Saint Regis Mohawk Tribe will shore up revenue from its top-selling dry eye drug Restasis in the short term.
Topic Company Analysis
Datamonitor Healthcare
By Zara Fulton 07 Oct 2017
Alnylam’s high stakes investment in RNAi therapeutics delivers a major short-term win for stakeholders, but long-term commercial success is still in question.
Topic BioPharmaceutical